|
|
|
GSK Forecast
Recent GSK Price |
|
GSK Forecast Price |
$43.35 |
+5.42% |
$45.70 |
As of 2024-05-03
Recent GSK Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
3 |
3 |
2 |
1 |
Buy ratings: |
0 |
0 |
0 |
0 |
Hold ratings: |
3 |
3 |
3 |
4 |
Sell ratings: |
1 |
1 |
1 |
1 |
Strong sell ratings: |
2 |
2 |
2 |
2 |
Average rating: |
2.89 |
2.89 |
3.13 |
3.38 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the GSK plc forecast (traded under symbol GSK) for one year forward price target at the top of this page, we have presented the average GSK forecast for forward target price across the 4 analysts covering GSK, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median GSK forecast price target (median being the middle where half of analysts had a higher GSK forecast and half had a lower GSK forecast, which is a different metric than the average or mean) was $45.5 as of 2024-05-03, while the
highest GSK forecast in the analyst group was $49.5, and the lowest GSK forecast in the analyst group was
$42.3, with a standard deviation of $2.976. Get the latest Zacks research report on GSK — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Name: |
GSK plc |
Website: |
www.gsk.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding GSK: |
12 (see which ones) |
Total Market Value Held by ETFs: |
$214,670,215 |
Total Market Capitalization: |
$125,834,000,000 |
% of Market Cap. Held by ETFs: |
0.17% |
|
|
|
|
Quotes delayed 20 minutes
|
Hold (2.11 out of 4)
3rd percentile
|
PARTNER NEWS:Thu, May 2, 8:02 AM, Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
Wed, May 1, 5:05 AM, Zacks
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
|
|